Overview 

Progeria, also known as Hutchinson-Gilford Progeria Syndrome (HGPS), is an extremely rare, progressive genetic disorder characterised by symptoms of accelerated ageing in children.. Progeria is caused by a mutation in the LMNA gene, which results in the production of an aberrant form of lamin A protein called progerin. Progerin accumulates abnormally in the nuclear lamina near the inner nuclear membrane, disrupting normal physiological processes at the nuclear, cellular and tissue levels. This alteration leads to systemic disorders, precipitating symptoms of accelerated ageing and premature death.^1,2

Clinical presentation

Children with progeria appear healthy at birth, however, profound failure-to-thrive follows during the first year, accompanied by issues associated with the skin, hair, skeletal and cardiovascular systems. Symptoms resemble characteristics of accelerated ageing and ultimately lead to death from cardiovascular complications.

Physical features

Progeria typically presents with a distinct set of facial features that appear during the first year. These include:

• Small face with disproportionately large head
• Prominent scalp veins
• Prominent eyes with loss of eyebrows and eyelashes
• Pinched nose, with a narrow nasal bridge and tip
• Thin vermilion of upper & lower lips, with bluish discolouration

Other common physical features include

• Thinning and wrinkled skin with hair loss
• Delayed eruption and absence of primary teeth
• Alopecia
• Nail dystrophy
• Progressive joint contractures and osteoporosis

Growth and developmental delay

Children with progeria exhibit severe growth failure regardless of adequate nutritional intake, resulting in a short stature and loss of subcutaneous fat. Developmental milestones may also be delayed, such as sitting, crawling, walking and puberty. Mental development progresses as normal.

Cardiovascular dysfunctions

Cardiovascular complications are the main cause of mortality in children with progeria. Symptoms such as chest pain, heart murmurs and arrhythmias arise from an early age, and lead to the development of cardiovascular disease, directly causing death as a result of complications from atherosclerosis, vascular stiffening and calcification, electrocardiographic alterations and ventricular dysfunctions. Death occurs between ages 6-20, with an average life expectancy of 14.5 years without surgery and targeted treatment, and 17-19.5 years with treatment.³

Diagnosis of progeria

The diagnosis of progeria involves a combination of clinical assessment, genetic testing, biochemical analysis, and imaging studies. Upon clinical examination, a healthcare provider may suspect progeria based on the characteristic physical features, growth delay, cardiovascular symptoms, while genetic testing is used to identify the mutation in the LMNA gene and confirm the diagnosis. 

Additionally, biochemical analyses and imaging studies such as protein assays, X-rays, MRI scans and echocardiography are routinely used to assess disease progression, such that symptom management strategies can be initiated in a timely manner to improve outcomes and quality of life for the patient.⁴

Clinical assessment

A thorough clinical exam of a progeria patient is conducted prior to genetic testing. This includes assessment of the characteristic clinical features of progeria, along with obtaining the child’s medical history, anthropometric and physiological measurements, such as measuring height and weight, testing hearing and vision, observing measurements on a growth curve chart, and measuring vital signs such as blood pressure, body temperature, heart and respiratory rates.

Genetic Testing for LMNA Gene Mutation

Genetic testing involves the examination of a patient’s DNA, which can reveal disease-causing mutations within a specific gene, confirming a prospective diagnosis. This method remains the gold standard for diagnosing progeria, and testing is typically done through blood sampling. Progeria is a rare autosomal dominant disease triggered by a single nucleotide mutation c.1824C>T in exon 11 (p.G608G), which leads to the production of an abnormal form of lamin A protein called progerin. Genetic testing can identify the presence of this mutation and confirm the diagnosis of progeria in affected individuals.⁵ 

Molecular and Biochemical Testing

Molecular and biochemical tests may also be conducted to assess the levels of progerin and other related proteins in the blood. Elevated levels of progerin are characteristic of progeria and contribute to the accelerated ageing process. These tests can help monitor disease progression and the effectiveness of treatment interventions. They also provide valuable insights into the underlying mechanisms of progeria and aid in the development of targeted therapies.

Imaging studies

Imaging studies are essential for evaluating the structural and functional abnormalities associated with progeria. 

X-rays 

Routinely used to assess new or progressing bone abnormalities in children with progeria. Early detection of skeletal abnormalities such as avascular necrosis, coxa valga, bone density, fractures and joint contractures can help guide treatment strategies to improve quality of life.

Echocardiography 

Non-invasive test that uses sound waves to create detailed images of the heart’s structure and function. Echocardiograms can detect complications such as thickening of the heart muscle (hypertrophy), valve problems, and atherosclerotic plaques. This is critical for early detection and management of cardiovascular dysfunctions as they rise in children with progeria.⁶ 

Computed tomography (CT) scans and magnetic resonance imaging (MRI) 

Provide detailed cross-sectional images of internal organs and tissues, and are often used to evaluate organ involvement in progeria. CT scans assess the condition of blood vessels, detect calcifications and evaluate organ size and structure while MRI scans are particularly useful for assessing brain development and detecting abnormalities within the brain. Together, these techniques help identify and monitor complications such as vascular calcifications, brain abnormalities and gastrointestinal issues in children with progeria. 

Treatment approaches

Medications

Farnesyl transferase (FTase) inhibitors

Progerin is produced as a result of a point mutation in the LMNA gene. This mutation disrupts the final post-translational modification processes that produce a functional lamin A protein. One such process is the removal of an attached lipid molecule called a farnesyl group, which does not occur in progerin. Permanent farnesylation in progerin increases the hydrophobicity of the protein, allowing its attachment to the nuclear membrane, disrupting normal cellular function. 

Farnesyl transferase inhibitors work by blocking the farnesylation process in the final stages of progerin production, inhibiting the production and accumulation of progerin within cells. Lonafarnib is the first and only U.S. Food and Drug Administration (FDA)-approved treatment specifically indicated for progeria. Clinical trials investigating the use of Lonafarnib in progeria showed effective results, with significant improvements in weight gain, skeletal rigidity, and vascular stiffness in children with progeria. The approval marked a significant milestone in the management of this condition.⁷

Statins

Statins are cholesterol-lowering medications that inhibit a key enzyme involved in cholesterol production, HMG-CoA reductase. By blocking this enzyme, statins reduce the production of cholesterol in the liver, leading to decreased levels of the harmful LDL cholesterol in the bloodstream. In individuals with progeria, statins are used not only for their cholesterol-lowering effects, but also for their potential to improve cardiovascular function. 

Progeria is associated with premature atherosclerosis, where the arteries become narrowed and hardened due to plaque buildup. Statins can help reduce this plaque formation, lowering the risk of cardiovascular events such as heart attacks and strokes. Studies have shown that statins may improve vascular function and delay the progression of atherosclerosis in children with progeria, offering cardiovascular protection.⁸

Supportive therapies

Physical therapy for mobility and strength 

Physical therapy plays a vital role in managing progeria by improving mobility, strength, and flexibility. Range-of-motion exercises are crucial in maintaining joint mobility and preventing joint contractures, which can limit movement and contribute to discomfort. Physical therapists can develop individualised exercise programs that focus on stretching and strengthening muscles, improving posture, and enhancing balance and coordination. Additionally, adaptive equipment and assistive devices such as wheelchairs, walkers, and orthotic devices can help improve mobility and independence in daily activities.

Occupational therapy for daily living skills 

Occupational therapy can help address certain challenges that individuals with progeria face in performing activities of daily living (ADLs), such as bathing, dressing, and feeding. Self-care strategies and adaptive techniques to conserve energy and minimise fatigue can be developed to overcome limitations and promote independence in daily tasks. 

Occupational therapists may also recommend home modifications to enhance safety and accessibility, such as installing grab bars in the bathroom or using raised toilet seats, and adaptive tools for self-care tasks, such as modified utensils and dressing aids to further enhance independence and quality of life.⁹

Nutritional support 

Children with progeria often have difficulty gaining weight due to their accelerated metabolism and reduced subcutaneous fat. A high-calorie diet rich in nutrients is recommended to support weight gain and overall growth. Nutritional supplements or fortified foods may be prescribed to ensure adequate calorie intake, and vitamin supplementation, in particular vitamin D and calcium are often recommended to prevent bone loss.

Summary

Early detection of progeria is critical for initiating appropriate interventions and improving quality of life. While there is no cure for the condition, early diagnosis allows for timely implementation of treatment strategies to manage symptoms and improve quality of life. With early detection, healthcare professionals can closely monitor cardiovascular health, bone development, and overall growth. This proactive approach helps in the prevention or early treatment of complications associated with progeria. 

Additionally, specialised care from a multidisciplinary team can assist in early management strategies, which may include supportive therapies, and nutritional interventions. These interventions aim to address the unique challenges posed by progeria and enhance the quality of life of affected children.